Skip to main content

WaferGen's Q1 Revenues Drop 10 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today reported that its first-quarter revenues declined 10 percent year over year.

The Fremont, Calif.-based firm generated total revenues of $351,000 for the three-month period ended March 31, compared to $390,000 for the first quarter of 2010. WaferGen said that its revenues were derived from a combination of one or more of its SmartChip Systems, SmartChip Panels, and/or SmartChip Gene Expression Profiling Services.

The firm's net loss for the quarter was $3.8 million, or $.09 per share, versus a loss of $4.6 million, or $.14 per share, for Q1 2010. For the first quarter of 2011, the company reported an unrealized gain of $491,000 on fair value of warrants, compared to an unrealized loss of $1.9 million for the same quarter in 2010.

WaferGen's R&D expenses increased 40 percent to $2.1 million from $1.5 million, while its SG&A spending jumped 69 percent to $2.2 million from $1.3 million. Its sales and marketing expenses increased primarily due to additional staff and promotional activities following the commercialization of its SmartChip Systems and services.

WaferGen finished the quarter with $3.4 million in cash, cash equivalents, and restricted cash.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.